Kura Oncology, Inc. (NASDAQ:KURA) Receives $28.00 Consensus Target Price from Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $28.00.

A number of analysts have recently weighed in on the company. Zacks Research cut Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. UBS Group raised their target price on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, November 14th. Barclays restated an “overweight” rating and set a $28.00 price target (up previously from $11.00) on shares of Kura Oncology in a research report on Monday, November 24th. Finally, Leerink Partners set a $20.00 price objective on shares of Kura Oncology and gave the company an “outperform” rating in a research report on Tuesday, January 13th.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 15,485 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $173,122.30. Following the completion of the transaction, the insider directly owned 225,454 shares of the company’s stock, valued at $2,520,575.72. This represents a 6.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Teresa Brophy Bair sold 11,208 shares of Kura Oncology stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $94,819.68. Following the sale, the insider directly owned 226,931 shares in the company, valued at $1,919,836.26. The trade was a 4.71% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 104,411 shares of company stock valued at $1,035,994. 6.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its stake in shares of Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after acquiring an additional 3,072 shares during the period. Allworth Financial LP increased its stake in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after acquiring an additional 1,553 shares during the period. PNC Financial Services Group Inc. raised its holdings in Kura Oncology by 127.2% during the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after purchasing an additional 3,769 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after purchasing an additional 9,958 shares during the period. Finally, Brevan Howard Capital Management LP bought a new position in Kura Oncology during the 2nd quarter valued at $80,000.

Kura Oncology Stock Down 8.3%

Shares of NASDAQ:KURA opened at $7.40 on Tuesday. The company’s fifty day moving average is $9.84 and its two-hundred day moving average is $9.10. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12. Kura Oncology has a 1-year low of $5.41 and a 1-year high of $12.49. The stock has a market capitalization of $643.95 million, a price-to-earnings ratio of -2.98 and a beta of 0.23.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The business had revenue of $20.75 million for the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. Equities analysts anticipate that Kura Oncology will post -2.44 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.